Muneer Siraj, Siddiqui Imran, Majid Hafsa, Zehra Nawazish, Jafri Lena, Khan Aysha Habib
Department of Pathology and Laboratory Medicine, Aga Khan University, Stadium Road, P.O. Box 3500, Karachi, 74800, Pakistan.
Ann Med Surg (Lond). 2022 Jan 5;73:103227. doi: 10.1016/j.amsu.2021.103227. eCollection 2022 Jan.
The trend of prescribing VD preparations for nonspecific body aches and self-medication has increased significantly. The importance of vitamin D toxicity (VDT) has been underestimated and under recognized. This study was done to determine the frequency toxicity (>150 ng/ml) in subjects for 25-hydroxyvitamin D (25OHD) and evaluate the vitamin D (VD) supplements used by these subjects.
This descriptive cross-sectional study was conducted at the Section of Chemical Pathology, Aga Khan University Hospital Karachi from April 2020 to March 2021. Subjects with 25OHD toxicity were contacted and information related to history of calcium and VD supplementation were collected. The statistical analysis was performed using the Microsoft Excel 2016.
Over a year period 105398 subjects were tested for serum 25OHD, of which 0.34% (n = 364) subjects had 25OHD level of >150 ng/ml. After satisfying exclusion criteria 186 subjects (78 were <18 years of age and 108 were adults) were included in final analysis. All of these were using VD supplements and the main indications were delayed growth/short height (43.7%, n = 34) and aches or pains in (54.6%, n = 59) in pediatric and adult subjects respectively.Most of the subjects were taking supplements orally (74.1%, n = 138). Commonly prescribed preparation in adults and pediatric was 200,000 IU (70.4%, n = 76) and 400 IU (35.9%, n = 28) respectively. Most subjects took supplements for 1-3 months (68.3%, n = 127). Stated total supplementation ranged from 20,000 IU to 3600,000 IU in pediatric subjects and 200,000 IU to 96,00,000 IU in adults.
Supplementation is a leading cause of potential toxic levels of 25OHD. The condition can be prevented by careful use of VD supplements and consistent monitoring.
为非特异性身体疼痛开具维生素D制剂及自我用药的趋势显著增加。维生素D毒性（VDT）的重要性一直被低估和认识不足。本研究旨在确定25-羟基维生素D（25OHD）水平＞150 ng/ml的受试者中毒性发生频率，并评估这些受试者使用的维生素D（VD）补充剂。
本描述性横断面研究于2020年4月至2021年3月在卡拉奇阿迦汗大学医院化学病理学科室进行。联系了25OHD中毒的受试者，并收集了与钙和VD补充史相关的信息。使用Microsoft Excel 2016进行统计分析。
在一年时间里，对105398名受试者进行了血清25OHD检测，其中0.34%（n = 364）的受试者25OHD水平＞150 ng/ml。在满足排除标准后，186名受试者（78名＜18岁，108名成年人）被纳入最终分析。所有这些受试者都在使用VD补充剂，主要适应症在儿科和成人受试者中分别为生长发育迟缓/身高矮小（43.7%，n = 34）和疼痛（54.6%，n = 59）。大多数受试者通过口服补充（74.1%，n = 138）。成人和儿科常用的制剂分别为200,000 IU（70.4%，n = 76）和400 IU（35.9%，n = 28）。大多数受试者补充1 - 3个月（68.3%，n = 127）。儿科受试者宣称的总补充量为20,000 IU至3,600,000 IU，成人受试者为200,000 IU至9,600,000 IU。
补充是导致25OHD潜在中毒水平的主要原因。通过谨慎使用VD补充剂并持续监测可预防这种情况。
